Biogen News and Research

RSS

This panel will decide whose medicine to make affordable. Its choice will be tricky.

Catherine Reitzel's multiple sclerosis medication costs nearly $100,000 a year. Kris Garcia relies on a drug for a blood-clotting disorder that runs $10,000 for a three-day supply. And Mariana Marquez-Farmer would likely die within days without her monthly $300 vial of insulin.

25 May 2023

Targeting mucus plugs could help prevent deaths from COPD, study suggests

A retrospective analysis of patient data from the COPDGene study suggests that targeting mucus plugs could help prevent deaths from chronic obstructive pulmonary disease-;the fourth leading cause of death in the United States.

22 May 2023

The role of RNA splicing in one of the deadliest forms of pancreatic cancer

In this interview, we spoke to Adrian Krainer, a Professor at Cold Spring Harbor Laboratory, about his latest research into the role of RNA splicing in one of the deadliest forms of pancreatic cancer.

22 May 2023

Newly identified genetic variant provides protection from Alzheimer's disease

A single patient can spark new research questions and provide answers about a disease. And when a new case is identified, investigators can make connections between them that can lead to even more powerful and persuasive ideas about cause and treatment.

15 May 2023

Higher exposure to fine particulate pollution may raise dementia risk

Exposure to fine particulate matter (PM2.5) air pollution is linked to a heightened risk of dementia, even at levels below current US, UK and European air quality standards, finds research published by The BMJ.

6 Apr 2023

Air pollution associated with increased risk of developing dementia

Exposure to fine particulate air pollutants (PM2.5) may increase the risk of developing dementia, according to a new meta-analysis from Harvard T.H. Chan School of Public Health.

6 Apr 2023

Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022.

From Quanterix 12 Dec 2022

The business of clinical trials is booming. Private equity has taken notice.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.

2 Dec 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

New Community of Experts launched to harness social media data for patient-centric drug development

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has launched a new Community of Experts (CoE) to harness real-world data from social media.

21 Nov 2022

Amyloid-PET scanning has misled the FDA into granting approval for Aduhelm

Last year, the FDA gave accelerated approval of the antibody aducanumab (marketed as Aduhelm by Biogen) for the treatment of Alzheimer's disease.

16 Nov 2022

Decline in specific protein levels linked to Alzheimer’s disease, not buildup of amyloid plaques

New research from the University of Cincinnati bolsters a hypothesis that Alzheimer's disease is caused by a decline in levels of a specific protein, contrary to a prevailing theory that has been recently called into question.

5 Oct 2022

New genetically-targeted MND therapy could be a turning point for patient care

Scientists believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care, after the results of a Phase 3 clinical trial showed significant physical benefits for patients after 12 months.

21 Sep 2022

Study helps understand how dietary therapies work for epilepsy

Calorie restriction has long been associated with reduced seizures in epilepsy. New research from Boston Children's Hospital helps explain how fasting affects neurons in the brain and could lead the way to new approaches that would avoid the need for fasting or restrictive diets. The findings were published August 30 in the journal Cell Reports.

9 Sep 2022

Study finds a declining trend in use of medications for sleep disturbance among Americans

Americans aren't turning to pharmaceutical options as often in the never-ending battle for a good night's sleep.

16 Aug 2022

17 recommendations for better communication with study participants affected by early stopping of clinical trials

Participants in clinical trials can feel abandoned and adrift when their studies end early and they are the last to be informed, or they hear about it first from news or social media.

2 Aug 2022

Age-related increases in brain inflammation may link Alzheimer's disease risk with sleep disturbance

A multisite research team from the University of California, Irvine, the University of Wisconsin–Madison and Wake Forest University has discovered that brain inflammation may link Alzheimer's disease risk with sleep disturbance, which may aid early detection and prevention efforts by identifying novel treatment targets at preclinical stages.

13 Jul 2022

Researchers discover two important novel aspects of APOE4 gene in Alzheimer's patients

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S.

23 Jun 2022

New approach to elevate health and well-being by optimizing late-life brain capital

Within many societies and cultures around the world, older adults are too often undervalued and underappreciated, according to a new article in the journal Innovation in Aging.

18 May 2022

Landmark $20 million gift received to establish Mount Sinai-Royalty Pharma Alliance for Health Equity Research

Marking a major advance in its efforts to achieve equity in the delivery of health care, the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) announced today that its Institute for Health Equity Research (IHER) has received a landmark $20 million gift over four years from Royalty Pharma plc and certain members of its management team.

16 May 2022